Effects of prazosin, clonidine, and propranolol on the elevations in brain reward thresholds and somatic signs associated with nicotine withdrawal in rats

Psychopharmacology

Volumn 212, Issue 4, 2010, Pages 485-499

  Bruijnzeel, Adrie W ^a   Bishnoi, Mahendra ^a   Van Tuijl, Irma A ^a   Keijzers, Kim F M ^a   Yavarovich, Kate R ^a   Pasek, Tim M ^a   Ford, Jenna ^a   Alexander, Jon C ^a   Yamada, Hidetaka ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Adrenergic receptors; Brain reward function; Clonidine; Nicotine; Norepinephrine; Prazosin; Propranolol; Rats; Withdrawal

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR; CLONIDINE; MECAMYLAMINE; PRAZOSIN; PROPRANOLOL;

AFFECT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN FUNCTION; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG MEGADOSE; LOW DRUG DOSE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REWARD; SMOKING CESSATION; SYMPTOMATOLOGY; WITHDRAWAL SYNDROME;

ADRENERGIC ALPHA-1 RECEPTOR ANTAGONISTS; ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BEHAVIOR, ANIMAL; CLONIDINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; NICOTINE; NICOTINIC AGONISTS; NICOTINIC ANTAGONISTS; PRAZOSIN; PROPRANOLOL; RATS; RATS, WISTAR; REACTION TIME; REINFORCEMENT (PSYCHOLOGY); REWARD; SUBSTANCE WITHDRAWAL SYNDROME; TOBACCO USE DISORDER;

EID: 78651286162     PISSN: 00333158     EISSN: 14322072     Source Type: Journal    
DOI: 10.1007/s00213-010-1970-0     Document Type: Article

References (75)

1. Ahmed SH, Kenny PJ, Koob GF, Markou A (2002) Neurobiological evidence for hedonic allostasis associated with escalating cocaine use. Nat Neurosci 5:625-626
2. American Psychiatric Association (2000) Diagnostic and statistical manual of mental disorders, 4th ed., text revision edn. American Psychiatric, Washington, DC
3. Barr AM, Markou A (2005) Psychostimulant withdrawal as an inducing condition in animal models of depression. Neurosci Biobehav Rev 29:675-706
4. Bruijnzeel AW, Gold MS (2005) The role of corticotropin-releasing factor-like peptides in cannabis, nicotine, and alcohol dependence. Brain Res Brain Res Rev 49:505-528
5. Bruijnzeel AW, Lewis B, Bajpai LK, Morey TE, Dennis DM, Gold M (2006) Severe deficit in brain reward function associated with fentanyl withdrawal in rats. Biol Psychiatry 59:477-480
6. Bruijnzeel AW, Zislis G, Wilson C, Gold MS (2007) Antagonism of CRF receptors prevents the deficit in brain reward function associated with precipitated nicotine withdrawal in rats. Neuropsychopharmacology 32:955-963
7. Bruijnzeel AW, Prado M, Isaac S (2009) Corticotropin-releasing factor-1 receptor activation mediates nicotine withdrawal-induced deficit in brain reward function and stress-induced relapse. Biol Psychiatry 66:110-117
8. Buccafusco JJ, Lapp CA, Westbrooks KL, Ernsberger P (1995) Role of medullary I1-imidazoline and alpha 2-adrenergic receptors in the antihypertensive responses evoked by central administration of clonidine analogs in conscious spontaneously hypertensive rats. J Pharmacol Exp Ther 273:1162-1171
9. Cahill L, Prins B, Weber M, McGaugh JL (1994) Beta-adrenergic activation and memory for emotional events. Nature 371:702-704
10. Carlezon WA Jr (2003) Place conditioning to study drug reward and aversion. Meth Mol Med 84:243-249
11. Coupar IM (1992) Effect of alpha 2-adrenoceptor agonists on the expression of morphine-withdrawal in rats. Naunyn Schmiedebergs Arch Pharmacol 345:553-557
12. Cryan JF, Bruijnzeel AW, Skjei KL, Markou A (2003) Bupropion enhances brain reward function and reverses the affective and somatic aspects of nicotine withdrawal in the rat. Psychopharmacology (Berl) 168:347-358
13. Damaj MI, Carroll FI, Eaton JB, Navarro HA, Blough BE, Mirza S, Lukas RJ, Martin BR (2004) Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. Mol Pharmacol 66:675-682
14. Debruyne D, Sobrio F, Hinschberger A, Camsonne R, Coquerel A, Barré L (2003) Short-term pharmacokinetics and brain distribution of mecamylamine as a preliminary to carbon-11 labeling for nicotinic receptor investigation. J Pharm Sci 92:1051-1057
15. Delfs JM, Zhu Y, Druhan JP, Aston-Jones G (2000) Noradrenaline in the ventral forebrain is critical for opiate withdrawal-induced aversion. Nature 403:430-434
16. Dong J, Blier P (2001) Modification of norepinephrine and serotonin, but not dopamine, neuron firing by sustained bupropion treatment. Psychopharmacology (Berl) 155:52-57
17. Eisenach JC, De KM, Klimscha W (1996) alpha(2)-Adrenergic agonists for regional anesthesia. A clinical review of clonidine (1984-1995). Anesthesiology 85:655-674
18. Epping-Jordan MP, Watkins SS, Koob GF, Markou A (1998) Dramatic decreases in brain reward function during nicotine withdrawal. Nature 393:76-79
19. Ernsberger P, Meeley MP, Mann JJ, Reis DJ (1987) Clonidine binds to imidazole binding sites as well as alpha 2-adrenoceptors in the ventrolateral medulla. Eur J Pharmacol 134:1-13
20. Fenton HM, Liebman JM (1982) Self-stimulation response decrement patterns differentiate clonidine, baclofen and dopamine antagonists from drugs causing performance deficit. Pharmacol Biochem Behav 17:1207-1212
21. Ferris RM, Maxwell RA, Cooper BR, Soroko FE (1982) Neurochemical and neuropharmacological investigations into the mechanisms of action of bupropion.HCl-a new atypical antidepressant agent. Adv Biochem Psychopharmacol 31:277-286
22. Fryer JD, Lukas RJ (1999) Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J Pharmacol Exp Ther 288:88-92
23. Fuentealba JA, Forray MI, Gysling K (2000) Chronic morphine treatment and withdrawal increase extracellular levels of norepi- nephrine in the rat bed nucleus of the stria terminalis. J Neurochem 75:741-748
24. Garcia-Sevilla JA, Zis AP, Hollingsworth PJ, Greden JF, Smith CB (1981) Platelet alpha 2-adrenergic receptors in major depressive disorder. Binding of tritiated clonidine before and after tricyclic antidepressant drug treatment. Arch Gen Psychiatry 38:1327-1333
25. Georges F, Aston-Jones G (2003) Prolonged activation of mesolimbic dopaminergic neurons by morphine withdrawal following clonidine: Participation of imidazoline and norepinephrine receptors. Neuropsychopharmacology 28:1140-1149
26. Georges F, Caille S, Vouillac C, Le MC, Stinus L (2005) Role of imidazoline receptors in the anti-aversive properties of clonidine during opiate withdrawal in rats. Eur J Neurosci 22:1812-1816
27. Glassman AH, Stetner F, Walsh BT, Raizman PS, Fleiss JL, Cooper TB, Covey LS (1988) Heavy smokers, smoking cessation, and clonidine. Results of a double-blind, randomized trial. JAMA 259:2863-2866
28. Gold MS, Redmond DE Jr, Kleber HD (1978) Clonidine blocks acute opiate-withdrawal symptoms. Lancet 2:599-602
29. Gourlay SG, Stead LF, Benowitz NL (2004) Clonidine for smoking cessation. Cochrane Database Syst Rev CD000058
30. Greenwell TN, Walker BM, Cottone P, Zorrilla EP, Koob GF (2009) The alpha1 adrenergic receptor antagonist prazosin reduces heroin self-administration in rats with extended access to heroin administration. Pharmacol Biochem Behav 91:295-302
31. Hall SM, Reus VI, Munoz RF, Sees KL, Humfleet G, Hartz DT, Frederick S, Triffleman E (1998) Nortriptyline and cognitivebehavioral therapy in the treatment of cigarette smoking. Arch Gen Psychiatry 55:683-690
32. Harris GC, Aston-Jones G (1993) Beta-adrenergic antagonists attenuate somatic and aversive signs of opiate withdrawal. Neuropsychopharmacology 9:303-311
33. Harrison AA, Liem YT, Markou A (2001) Fluoxetine combined with a serotonin-1A receptor antagonist reversed reward deficits observed during nicotine and amphetamine withdrawal in rats. Neuropsychopharmacology 25:55-71
34. Honda K, Takenaka T, Shiono K, Miyata-Osawa A, Nakagawa C (1985) Autonomic and antihypertensive activity of oral amosulalol (YM-09538), a combined alpha- and beta-adrenoceptor blocking agent in conscious rats. Jpn J Pharmacol 38:31-41
35. Hughes JR, Gust SW, Skoog K, Keenan RM, Fenwick JW (1991) Symptoms of tobacco withdrawal. A replication and extension. Arch Gen Psychiatry 48:52-59
36. Hughes JR, Stead LF, Lancaster T (2007) Antidepressants for smoking cessation. Cochrane Database Syst Rev CD000031
37. Hurt RD, Sachs DP, Glover ED, Offord KP, Johnston JA, Dale LC, Khayrallah MA, Schroeder DR, Glover PN, Sullivan CR, Croghan IT, Sullivan PM (1997) A comparison of sustainedrelease bupropion and placebo for smoking cessation. N Engl J Med 337:1195-1202
38. Hyttel J (1994) Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 9 (Suppl 1):19-26
39. Irvine EE, Cheeta S, File SE (1999) Time-course of changes in the social interaction test of anxiety following acute and chronic administration of nicotine. Behav Pharmacol 10:691-697
40. Jorenby DE, Leischow SJ, Nides MA, Rennard SI, Johnston JA, Hughes AR, Smith SS, Muramoto ML, Daughton DM, Doan K, Fiore MC, Baker TB (1999) A controlled trial of sustainedrelease bupropion, a nicotine patch, or both for smoking cessation. N Engl J Med 340:685-691
41. Koob GF (2008) Hedonic homeostatic dysregulation as a driver of drugseeking behavior. Drug Discov Today Dis Model 5:207-215
42. Koob GF, Le Moal M (2005) Plasticity of reward neurocircuitry and the 'dark side' of drug addiction. Nat Neurosci 8:1442-1444
43. Koob GF, Caine SB, Parsons L, Markou A, Weiss F (1997) Opponent process model and psychostimulant addiction. Pharmacol Biochem Behav 57:513-521
44. Kornetsky C, Esposito RU (1979) Euphorigenic drugs: Effects on the reward pathways of the brain. Fed Proc 38:2473-2476
45. Kosten TA (1994) Clonidine attenuates conditioned aversion produced by naloxone-precipitated opiate withdrawal. Eur J Pharmacol 254:59-63
46. Liebman JM, Hall N, Prowse J (1982) Effects of various catecholamine receptor antagonists, muscle relaxation and physical hindrance on shuttlebox self-stimulation. Pharmacol Biochem Behav 16:785-790
47. Lin Y, de Vaca SC, Carr KD, Stone EA (2007) Role of alpha(1)- adrenoceptors of the locus coeruleus in self-stimulation of the medial forebrain bundle. Neuropsychopharmacology 32:835-841
48. Malin DH, Lake JR, Newlin-Maultsby P, Roberts LK, Lanier JG, Carter VA, Cunningham JS, Wilson OB (1992) Rodent model of nicotine abstinence syndrome. Pharmacol Biochem Behav 43:779-784
49. Malin DH, Lake JR, Carter VA, Cunningham JS, Hebert KM, Conrad DL, Wilson OB (1994) The nicotinic antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology (Berl) 115:180-184
50. Manion ST, Gamble EH, Li H (2007) Prazosin administered prior to inescapable stressor blocks subsequent exaggeration of acoustic startle response in rats. Pharmacol Biochem Behav 86:559-565
51. Markou A, Koob GF (1991) Postcocaine anhedonia. An animal model of cocaine withdrawal. Neuropsychopharmacology 4:17-26
52. Markou A, Koob GF (1992) Construct validity of a self-stimulation threshold paradigm: Effects of reward and performance manipulations. Physiol Behav 51:111-119
53. Markou A, Kosten TR, Koob GF (1998) Neurobiological similarities in depression and drug dependence: A self-medication hypothesis. Neuropsychopharmacology 18:135-174
54. McGaugh JL (2000) Memory-a century of consolidation. Science 287:248-251
55. Millan MJ, Rivet JM, Gobert A, Canton H, Veiga S, Bervoets K (1994) 5-HT1A receptors and the tail-flick response. VI. Intrinsic alpha 1A-adrenoceptor antagonist properties can mask the actions of 5-HT1A receptor agonists in the spontaneous tail-flick paradigm. J Pharmacol Exp Ther 269:121-131
56. Olds ME, Domino EF (1969) Comparison of muscarinic and nicotinic cholinergic agonists on self-stimulation behavior. J Pharmacol Exp Ther 166:189-204
57. Ozdogan UK, Lahdesmaki J, Scheinin M (2003) Influence of prazosin and clonidine on morphine analgesia, tolerance and withdrawal in mice. Eur J Pharmacol 460:127-134
58. Prochazka AV, Weaver MJ, Keller RT, Fryer GE, Licari PA, Lofaso D (1998) A randomized trial of nortriptyline for smoking cessation. Arch Intern Med 158:2035-2039
59. Rylkova D, Boissoneault J, Isaac S, Prado M, Shah HP, Bruijnzeel AW (2008) Effects of NPY and the specific Y1 receptor agonist [D-His(26)]-NPY on the deficit in brain reward function and somatic signs associated with nicotine withdrawal in rats. Neuropeptides 42:215-227
60. Schulteis G, Markou A, Gold LH, Stinus L, Koob GF (1994) Relative sensitivity to naloxone of multiple indices of opiate withdrawal: A quantitative dose-response analysis. J Pharmacol Exp Ther 271:1391-1398
61. Schulteis G, Markou A, Cole M, Koob GF (1995) Decreased brain reward produced by ethanol withdrawal. Proc Natl Acad Sci USA 92:5880-5884
62. Sellinger-Barnette MM, Mendels J, Frazer A (1980) The effect of psychoactive drugs on beta-adrenergic receptor binding sites in rat brain. Neuropharmacology 19:447-454
63. Shiffman S, Johnston JA, Khayrallah M, Elash CA, Gwaltney CJ, Paty JA, Gnys M, Evoniuk G, DeVeaugh-Geiss J (2000) The effect of bupropion on nicotine craving and withdrawal. Psychopharmacology (Berl) 148:33-40
64. Sparber SB, Meyer DR (1978) Clonidine antagonizes naloxoneinduced suppression of conditioned behavior and body weight loss in morphine-dependent rats. Pharmacol Biochem Behav 9:319-325
65. Sugrue MF (1983) Chronic antidepressant therapy and associated changes in central monoaminergic receptor functioning. Pharmacol Ther 21:1-33
66. Timmermans PB, Schoop AM, Kwa HY, Van Zwieten PA (1981) Characterization of alpha-adrenoceptors participating in the central hypotensive and sedative effects of clonidine using yohimbine, rauwolscine and corynanthine. Eur J Pharmacol 70:7-15
67. van Stegeren AH, Everaerd W, Cahill L, McGaugh JL, Gooren LJ (1998) Memory for emotional events: Differential effects of centrally versus peripherally acting beta-blocking agents. Psychopharmacology (Berl) 138:305-310
68. Wagena EJ, Knipschild P, Zeegers MP (2005) Should nortriptyline be used as a first-line aid to help smokers quit? Results from a systematic review and meta-analysis. Addiction 100:317-326
69. Watanabe T, Nakagawa T, Yamamoto R, Maeda A, Minami M, Satoh M (2003) Involvement of noradrenergic system within the central nucleus of the amygdala in naloxone-precipitated morphine withdrawal-induced conditioned place aversion in rats. Psychopharmacology (Berl) 170:80-88
70. Watkins SS, Stinus L, Koob GF, Markou A (2000) Reward and somatic changes during precipitated nicotine withdrawal in rats: Centrally and peripherally mediated effects. J Pharmacol Exp Ther 292:1053-1064
71. Wee S,Mandyam CD, Lekic DM, Koob GF (2008) Alpha 1-noradrenergic system role in increased motivation for cocaine intake in rats with prolonged access. Eur Neuropsychopharmacol 18:303-311
72. Wing VC, Shoaib M (2007) Examining the clinical efficacy of bupropion and nortriptyline as smoking cessation agents in a rodent model of nicotine withdrawal. Psychopharmacology (Berl) 195:303-313
73. Wise RA, Munn E (1995) Withdrawal from chronic amphetamine elevates baseline intracranial self-stimulation thresholds. Psychopharmacology (Berl) 117:130-136
74. Yang XM, Gorman AL, Dunn AJ (1990) The involvement of central noradrenergic systems and corticotropin-releasing factor in defensive-withdrawal behavior in rats. J Pharmacol Exp Ther 255:1064-1070
75. Zislis G, Desai TV, Prado M, Shah HP, Bruijnzeel AW (2007) Effects of the CRF receptor antagonist D-Phe CRF(12-41) and the alpha2-adrenergic receptor agonist clonidine on stress-induced reinstatement of nicotine-seeking behavior in rats. Neuropharmacology 58:958-966